# China NMPA Drug Inspection - Jilin Jichun Pharmaceutical Co., Ltd. - Niuhuang Jiedu Pills

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/jilin-jichun-pharmaceutical-co-ltd/208d3615-62dc-4a6f-8d00-f27c69258824/
Source feed: China

> China NMPA drug inspection for Jilin Jichun Pharmaceutical Co., Ltd. published December 04, 2017. Drug: Niuhuang Jiedu Pills. On December 4, 2017, the Shandong Provincial Food and Drug Administration announced that four batches of drugs from thre

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement from Shandong Provincial Food and Drug Administration Regarding 4 Batches of Drugs Failing Quality Inspections (Issue No. 9, 2017)
- Company Name: Jilin Jichun Pharmaceutical Co., Ltd.
- Publication Date: 2017-12-04
- Drug Name: Niuhuang Jiedu Pills
- Inspection Finding: The quality of the medicine does not meet the standard requirements; the non-compliant items are those specified in the inspection.
- Action Taken: Control measures such as sealing, seizing, suspending sales, and recalling products were implemented, and cases were filed against the relevant production enterprises and sampled units in accordance with the law.
- Summary: On December 4, 2017, the Shandong Provincial Food and Drug Administration announced that four batches of drugs from three pharmaceutical companies failed quality inspections. The inspections, conducted by the Linyi Municipal Food and Drug Inspection and Testing Center under the National Medical Products Administration (NMPA) regulatory framework, revealed that products did not meet established quality standards. Specifically, Jilin Tianguang Pharmaceutical Co., Ltd.'s Vitiligo Pills (batch numbers 20151102 and 20160601), Jilin Jichun Pharmaceutical Co., Ltd.'s Niuhuang Jiedu Pills (batch number 160202), and Sichuan Sanxingdui Pharmaceutical Co., Ltd.'s Yankening Tablets (batch number 160202) were found to be substandard. While the announcement did not detail the specific quality deficiencies, it highlighted a failure to comply with regulatory requirements. In response, the relevant municipal food and drug administration bureaus initiated immediate control measures, including sealing, seizing, suspending sales, and mandating recalls of the substandard drugs. Furthermore, investigations and legal proceedings have commenced against the implicated manufacturers and distribution units. Enterprises are required to thoroughly investigate the root causes of these quality failures, develop and implement comprehensive rectification plans, and proactively mitigate future risks to ensure public health and safety.

Company: https://www.globalkeysolutions.net/companies/jilin-jichun-pharmaceutical-co-ltd/84771b47-8aa9-48ed-aab2-fd7f24e016f0/